Search results for "PPAR"

showing 10 items of 1686 documents

Lussazione abituale del nervo ulnare al gomito: proposta di nuova tecnica chirurgica

2012

Settore MED/33 - Malattie Apparato Locomotorenervo ulnare lussazione trattamento chirurgico
researchProduct

Co-morbidities in patients with hip osteoarthritis and treated with ecoguided infiltrations of Hyaluronic acid: study of the effectiveness of the tre…

2014

Settore MED/33 - Malattie Apparato Locomotoreosteoarthritis co-morbidities ecoguided infiltrations hyaluronic acid
researchProduct

Fractures of the patella today: use of absorbable cerclage

2011

Settore MED/33 - Malattie Apparato Locomotorepatella absorbable cerclage
researchProduct

Polinucleotidi vs acido ialuronico nelle in filtrazioni ecoguidate dell'anca artrosica. Risultati preliminari

2012

Settore MED/33 - Malattie Apparato Locomotorepolinucleotidi acido ialuronico infiltrazioni artrosi anca
researchProduct

Mid-term results of isolated posterolateral corner reconstruction

2009

Isolated posterolateral corner (PLC) tears are relatively rare events. Various surgical techniques to treat posterolateral knee instability have been described; because surgical results are very much linked to cruciate reconstructions to date it is difficult to define whether one surgical procedure has better prognosis than another. The goal of this study is to determine the clinical outcome of PLC reconstruction following fibular-based technique. MATERIALS AND METHODS: We retrospectively evaluated a case series of patients who had received isolated PLC reconstruction between March 2005 and January 2007. 12 patients were surgically treated for isolated injuries and 10 patients were availabl…

Settore MED/33 - Malattie Apparato Locomotoreposterolateral corner knee injuries knee ligaments
researchProduct

Le localizzazioni extravertebrali della tubercolosi osteoarticolare

2011

Settore MED/33 - Malattie Apparato Locomotoretubercolosi extravertebrale osteomielite specifica debridement osteoarticolareartrodesi protesi
researchProduct

SINERGIE: FISIOTERAPIA E VISCOSUPPLEMENTAZIONE

2009

Settore MED/34 - Medicina Fisica E RiabilitativaSettore MED/33 - Malattie Apparato LocomotoreVISCOSUPPLEMENTAZIONE FISIOTERAPIA
researchProduct

Beliefs and preferences regarding biological treatments for severe asthma

2020

Background: Severe asthma is a serious condition with a significant burden on patients' morbidity, mortality, and quality of life. Some biological therapies targeting the IgE and interleukin-5 (IL5) mediated pathways are now available. Due to the lack of direct comparison studies, the choice of which medication to use varies. We aimed to explore the beliefs and practices in the use of biological therapies in severe asthma, hypothesizing that differences will occur depending on the prescribers’ specialty and experience. Methods: We conducted an online survey composed of 35 questions in English. The survey was circulated via the INterasma Scientific Network (INESNET) platform as well as throu…

Severe asthmaBehavior; Belief; Biological drug; Severe asthmainterleukine 5 IgEMULTICENTERDiseaseOmalizumabADD-ON THERAPYBehavior Belief Biological drug Severe asthmaDOUBLE-BLIND0302 clinical medicineMedicine and Health SciencesImmunology and AllergyEosinophil IL5 [Eos]030223 otorhinolaryngologyPulmonologistssevere asthma biological drug belief behavior3. Good healthBeliefSAFETYmedicine.druglcsh:Immunologic diseases. AllergyPulmonary and Respiratory Medicinemedicine.medical_specialtyEos: Eosinophil IL5ImmunologyBiological drugSpecialtylong-acting beta2-agonist OMASocio-culturaleSettore MED/10 - Malattie Dell'Apparato RespiratorioArticle03 medical and health sciencesQuality of life (healthcare)Omalizumab. OMA/IL5 Omalizumab plus anti-IL5 moleculeOMALIZUMABmedicineIntensive care medicineAsthmaBehaviorINterasma Scientific Network LABAbusiness.industryMEPOLIZUMABmedicine.diseaseEFFICACYICS inhaled corticosteroidsLIFE030228 respiratory systemImmunoglobulin E INESNETAllergistslcsh:RC581-607businessMepolizumab
researchProduct

Characteristics and treatment regimens across ERS SHARP severe asthma registries

2020

Little is known about the characteristics and treatments of patients with severe asthma across Europe, but both are likely to vary. This is the first study in the European Respiratory Society Severe Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) Clinical Research Collaboration and it is designed to explore these variations. Therefore, we aimed to compare characteristics of patients in European severe asthma registries and treatments before starting biologicals.This was a cross-sectional retrospective analysis of aggregated data from 11 national severe asthma registries that joined SHARP with established patient databases.Analysis of data from 3236 patients showed many …

Severe asthmaPediatricsMESH: RegistriesMESH: AsthmaCross-sectional studyRespiratory SystemMedizin[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract0302 clinical medicineMESH: BelgiumBelgiumMedicine researchAnti-Asthmatic AgentsRegistries030212 general & internal medicine[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology10. No inequality11 Medical and Health SciencesNetherlands2. Zero hungereducation.field_of_studySHARP CRCMESH: Administration InhalationMESH: Anti-Asthmatic Agents3. Good healthEuropeItalyMESH: PolandMESH: Swedenmedicine.drugPulmonary and Respiratory Medicinemedicine.medical_specialtyMESH: HungaryPopulationInvestigació mèdicaSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesMESH: Cross-Sectional StudiesAdministration InhalationMESH: SpainmedicineHumanseducationAsmaRetrospective StudiesAsthmaSwedenHungaryMESH: Humansbusiness.industrySettore MED/09 - MEDICINA INTERNAMESH: ItalyMESH: Retrospective StudiesRetrospective cohort studyOriginal Articlesasthmamedicine.diseaseAsthmaClinical trialCross-Sectional StudiesClinical research030228 respiratory systemSpainMESH: NetherlandsMESH: EuropePolandbusinessBody mass indexMepolizumabEuropean Respiratory Journal
researchProduct

Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter Study

2021

Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) affects around 60% of patients with severe eosinophilic asthma (SEA). Benralizumab was recently approved for SEA add-on treatment. Objective: To assess the real-world effectiveness of benralizumab in SEA with or without CRSwNP. Methods: We conducted a multicenter observational study, including patients with SEA treated with benralizumab for 24 weeks in 12 Italian specialized facilities. Asthma exacerbations, Asthma Control Test (ACT), lung function, oral corticosteroid (OCS) dosage, and eosinophil and basophil count in peripheral blood were recorded at baseline and after 4, 12, and 24 weeks. The 22-item Sino-Nasal Outcome Test (S…

Severe asthmaVital capacitymedicine.medical_specialtymedicine.drug_classSettore MED/10 - Malattie Dell'Apparato RespiratorioAntibodies Monoclonal HumanizedFEV1/FVC ratiochemistry.chemical_compoundNasal PolypsInternal medicinemedicineHumansImmunology and AllergyNasal polypsAnti-Asthmatic AgentsIL-5Nasal polypbusiness.industryMinimal clinically important differenceBenralizumabFunctional endoscopic sinus surgeryrespiratory systemEosinophilBenralizumabmedicine.diseaseAsthmaChronic rhinosinusitismedicine.anatomical_structureReal-worldchemistryChronic rhinosinusitiCorticosteroidbusinessHumanThe Journal of Allergy and Clinical Immunology: In Practice
researchProduct